Tetrapropylammonium → 1-(3-Isopropyl-1,2,4-oxadiazol-5-YL)piperidin-4-one

反応式

[CH3:1][CH:2]([C:4]1[N:8]=[C:7]([N:9]2[CH2:14][CH2:13][CH:12]([OH:15])[CH2:11][CH2:10]2)[O:6][N:5]=1)[CH3:3].C[N+]1([O-])CCOCC1.C([N+](CCC)(CCC)CCC)CC>ClCCl>[CH3:3][CH:2]([C:4]1[N:8]=[C:7]([N:9]2[CH2:10][CH2:11][C:12](=[O:15])[CH2:13][CH2:14]2)[O:6][N:5]=1)[CH3:1]

参加物

実験手順

1-[3-(Propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-ol (0.5 g) is dissolved in dichloromethane (75 mL) and 4 A molecular sieves (4 g) is added followed by N-methylmorpholine-N-oxide (1.52 g) and tetrapropylammonium perrhutenate (0.018 g) and the mixture is stirred at room temperature for 1 h. The reaction is filtered through celite and the filtrate is washed with water (2×50 mL). The combined aqueous layers are extracted with dichloromethane (100 mL). The organic layers are combined, dried over Na2SO4, filtered and concentrated to a dark liquid which crystallized upon standing to yield the title compound.